Concepedia

David W. End

DW

Statistics

Publications

17

Citations

1.1K

H-Index

15

Active since

1977

Affiliations

Johnson & Johnson (United States)(Current)

Johnson & Johnson (France)

Springhouse

Health and Human Development (2HD) Research Network

Virginia Commonwealth University Medical Center

David W. End is an author at Johnson & Johnson (United States) specializing in pharmacology, life sciences, and medicine.

Publications per year

1977–2011

17

Publications

17

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

Judith E. Karp, Jeffrey E. Lancet, Scott H. Kaufmann et al. · Blood · 2001 · 445 citations · Full text

, , +9

Phase I Trial and Pharmacokinetic Study of the Farnesyltransferase Inhibitor Tipifarnib in Children With Refractory Solid Tumors or Neurofibromatosis Type I and Plexiform Neurofibromas

Brigitte C. Widemann, Wanda L. Salzer, R.J. Arceci et al. · Journal of Clinical Oncology · 2006 · 145 citations · Full text

, , +17

The Action of Adenosine Analogs on PC12 Cells

Gordon Guroff, Geneva Dickens, David W. End et al. · Journal of Neurochemistry · 1981 · 93 citations

, , +13

The Induction of Ornithine Decarboxylase by Nerve Growth Factor and Epidermal Growth Factor in PC 12 Cells

Gordon Guroff, Geneva Dickens, David W. End · Journal of Neurochemistry · 1981 · 54 citations

, , +7

Effects of 12‐0‐tetradecanoylphorbol‐13‐acetate (TPA) on rat pheochromocytoma (PC12) cells: Interactions with epidermal growth factor and nerve growth factor

David W. End, N. Tolson, M.-L. Yu et al. · Journal of Cellular Physiology · 1982 · 39 citations

, , +9

1–5 of 17